亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車(chē)
企業(yè)會(huì)員第1年

湖北大華偉業(yè)醫(yī)藥化工有限公司  

該公司主要從事原料藥(API)及中間體生產(chǎn)和研發(fā)

搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
  • 暫無(wú)分類
聯(lián)系方式
  • 聯(lián)系人:艾天堯
  • 電話:027-59420981
  • 郵件:1933329534@qq.com
  • 傳真:430000
  • QQ:1933329534
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
奧扎格雷
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 湖北武漢市付款后3天內(nèi)
過(guò)期 長(zhǎng)期有效
更新 2014-02-09 09:04
 
詳細(xì)信息

奧扎格雷 
中文別名:奧扎格雷;反式-3-[4-(1H-咪唑-1-基甲基)苯基]-2-丙烯酸;(E)-4-(1-咪唑基甲基)肉桂酸鈉 
英文名稱:Ozagrel 
CAS號(hào):78712-43-3 
包裝規(guī)格:25kg紙板桶 
規(guī)格型號(hào):98%,醫(yī)藥級(jí)
分子式:C13H12N2O2 
分子量 :228.25 
用途:可抑制TXA2合成酶,具有抗血小板聚集和解除血管痙攣的作用。 臨床上用于蛛網(wǎng)膜下腔出血手術(shù)后血管痙攣及其并發(fā)腦缺血癥狀的改善。

Tel 18702770802
©2025 湖北大華偉業(yè)醫(yī)藥化工有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問(wèn)量:9605  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |